Keywords
Therapeutics ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

31 Search results.

Eligibility Type 2 Diabetes Mellitus NCT02004886

- 6/13/17 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005); ODM derived from: https://clinicaltrials.gov/show/NCT02004886

Eligibility Type 2 Diabetes NCT00612794

- 6/13/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00612794

Eligibility Type 2 Diabetes Mellitus NCT00605475

- 6/13/17 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00605475

Eligibility Schizophrenia NCT00686140

- 6/11/17 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00686140

Eligibility Schizophrenia NCT00538070

- 6/11/17 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00538070

Eligibility Schizophrenia NCT00611806

- 6/11/17 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00611806

Eligibility Schizophrenia NCT00791713

- 6/11/17 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER; ODM derived from: https://clinicaltrials.gov/show/NCT00791713

Eligibility Schizophrenia NCT00791167

- 6/11/17 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of the Dose Proportionality of Extended Release Paliperidone; ODM derived from: https://clinicaltrials.gov/show/NCT00791167

Eligibility Treatment-resistant Schizophrenia NCT01105481

- 6/11/17 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01105481

Eligibility Platelet Aggregation Inhibitors NCT00799396

- 6/10/17 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study); ODM derived from: https://clinicaltrials.gov/show/NCT00799396

Eligibility Pulmonary Hypertension NCT01156636

- 6/10/17 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT01156636

Eligibility Rheumatoid Arthritis NCT00538902

- 6/10/17 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate; ODM derived from: https://clinicaltrials.gov/show/NCT00538902